Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML0KWM)

• Drug Name: CAR-T cells targeting CD30 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-hodgkin lymphoma	2B33.5	Phase 2	[1]
leukaemia	2A60-2B33	Phase 1/2	[2]
Lymphoma	2A80-2A86	Phase 1/2	[2]
Multiple myeloma	2A83	Phase 1/2	[2]

• Cross-matching ID: TTD Drug ID: DML0KWM

Molecule-Related Drug Atlas

Drug(s) Targeting Lymphocyte activation antigen CD30 (TNFRSF8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brentuximab vedotin	DMWLC57	Hodgkin lymphoma	2B30	Approved	[3]
AFM13	DMN45IC	Hodgkin lymphoma	2B30	Phase 2	[4]
Iratumumab	DMI874B	Lymphoma	2A80-2A86	Phase 2	[5]
SGN-30	DMJ9M5D	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
TT11X	DMW3M7X	Hodgkin lymphoma	2B30	Phase 2	[7]
TT20X	DMHGI09	Aggressive cancer	2A00-2F9Z	Phase 2	[7]
4SCAR19 and 4SCAR30	DMUYFS1	B-cell lymphoma	2A86	Phase 1/2	[8]
Anti-CD30 CAR T cells	DM8139V	Lymphoma	2A80-2A86	Phase 1/2	[9]
CART30	DMLE8T9	Hodgkin lymphoma	2B30	Phase 1/2	[10]
CAR.CD30 cells	DM6ZXWY	Immune System disease	4A01-4B41	Phase 1/2	[11]
Brentuximab vedotin	DMWLC57	Hodgkin lymphoma	2B30	Approved	[3]
AFM13	DMN45IC	Hodgkin lymphoma	2B30	Phase 2	[4]
Iratumumab	DMI874B	Lymphoma	2A80-2A86	Phase 2	[5]
SGN-30	DMJ9M5D	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
TT11X	DMW3M7X	Hodgkin lymphoma	2B30	Phase 2	[7]
TT20X	DMHGI09	Aggressive cancer	2A00-2F9Z	Phase 2	[7]
4SCAR19 and 4SCAR30	DMUYFS1	B-cell lymphoma	2A86	Phase 1/2	[8]
Anti-CD30 CAR T cells	DM8139V	Lymphoma	2A80-2A86	Phase 1/2	[9]
CART30	DMLE8T9	Hodgkin lymphoma	2B30	Phase 1/2	[10]
CAR.CD30 cells	DM6ZXWY	Immune System disease	4A01-4B41	Phase 1/2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lymphocyte activation antigen CD30 (TNFRSF8)	TT2GM5R	TNR8_HUMAN	CAR-T-Cell-Therapy	[2]

References

• [1] ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
• [2] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [3] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [4] Clinical pipeline report, company report or official report of Affimed Therapeutics.
• [5] Utilizing CD30 expression as a rational target for therapy of lymphoma. J Hematol Oncol. 2012; 5(Suppl 1): A2.
• [6] The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002 Jul 1;62(13):3736-42.
• [7] Clinical pipeline report, company report or official report of Tessa Therapeutics
• [8] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [9] ClinicalTrials.gov (NCT02274584) CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
• [10] ClinicalTrials.gov (NCT02259556) CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
• [11] ClinicalTrials.gov (NCT02663297) Administration of T Lymphocytes for Prevention of Relapse of Lymphomas